You are here
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
SBC: Abzyme Therapeutics, LLC Topic: CBD161004
Alphaviruses, infection with which may cause encephalitis and death, are recognized as potential biological warfare agents. There are noapproved medical countermeasures against Alphaviruses. In Phase I, using Abzymes proprietary in vivo Self-Diversifying Camelid SingleDomain Antibody Library (SDALib) platform, broadly reactive single domain camelid VHH antibodies against equine encephalitis viral ...SBIR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: CREARE LLC Topic: CBD13109
Interfaces on existing military chemical/biological protection garments are not designed to fully eliminate macroscopic and microscopic air gaps at folds, fabric surfaces, or hook-and-loop closures, and thus do not provide a hermetic barrier against exposure. Creare is developing hermetic garment closure systems that seal macroscopic and microscopic gaps at interfaces and closures and provide high ...SBIR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: NANOGRIPTECH Topic: CBD13109
Future engagements (especially with near-peer threats) present the possibility of a wide range of anticipated operational situations involving the presence of chemical threat agents. With this, deployment of Military Working Dogs (MWDs) is likely. This creates a situational awareness that MWDs are potentially at risk from exposure to a wide range of hazardous chemicals. Potential threat agents inc ...SBIR Phase II 2018 Department of DefenseOffice for Chemical and Biological Defense